Mycobacterial Diseases Program

About Hsiri Therapeutics

Hsiri Therapeutics is a private, preclinical-stage biotech tackling the critical global health threat of antimicrobial resistance (AMR). The company is developing a pipeline of novel small molecules targeting drug-resistant mycobacterial, bacterial, and fungal infections, leveraging research from key academic collaborators. Hsiri has established a significant strategic partnership with Shionogi & Co., Ltd. for its mycobacterial programs and has received grant support from U.S. government agencies, positioning it to address substantial unmet medical needs in infectious diseases.

Therapeutic Areas